Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249183 | 1.00 | ACE2 (0.61) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL5869596 | 0.92 | ACE2 (0.63) | ACE2ACECYP11B1CYP11B2 | |
| SCHEMBL5870153 | 0.85 | ACE2 (0.64) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL8249141 | 0.85 | ACE2 (0.64) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL1656622 | 0.85 | ACE2 (0.64) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL1658782 | 0.84 | ACE2 (0.61) | ACE2ACENTSR1PSMB5 | |
| SCHEMBL8254552 | 0.84 | ACE2 (0.61) | ACE2ACENTSR1PSMB5 | |
| SCHEMBL1690694 | 0.84 | ACE2 (0.66) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL8249187 | 0.84 | ACE2 (0.66) | ACE2ACECYP11B1CYP11B2NTSR1 | |
| SCHEMBL8249161 | 0.84 | ACE2 (0.63) | ACE2ACECYP11B1CYP11B2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2012-01-12 | — | — | US | claimed |
| US-20100204286-A1 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICAL, INC. | 2010-08-12 | — | — | US | claimed |
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-07-23 | — | — | US | claimed |
| EP-2059234-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| US-20080234345-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | GENE LOGIC INC. (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008031014-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | claimed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | claimed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186014-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | ACE2 6/4885ACE 3/4885CYP11B1 2817/4885 |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE2 2/4885ACE 1/4885CYP11B1 256/4885 |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | ACE2 1/4885ACE 2/4885CYP11B1 3069/4885 |
| US-20120009183-A1 | METHOD FOR TREATMENT OF PANCREATITIS | AMY2A, PNLIP, ACE | ACE2 6/4885ACE 3/4885CYP11B1 2817/4885 |
| US-20080234345-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ACE, ACE2, CTRB2 | ACE2 2/4885ACE 1/4885CYP11B1 839/4885 |
| US-20100204286-A1 | METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ACE2, ACE, ACER2 | ACE2 1/4885ACE 2/4885CYP11B1 655/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | ACE2 2/4885ACE 1/4885CYP11B1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.